Business

Philips appoints Julia Strandberg as Chief Business Leader

Business






March 13, 2023

Amsterdam, Netherlands – Royal Phillips (NYSE: PHG, AEX: PHIA), a global leader in healthcare technology, today announced the appointment of Julia Strandberg as Chief Business Leader of its Connected Care business, effective April 24, 2023. Ms. Strandberg will join Philips’ Executive Committee, reporting to Roy Jakobs, CEO of Philips. As of April 1, 2023, Philips Connected Care businesses will include Monitoring, Sleep & Respiratory Care and Enterprise Informatics businesses.

Ms. Strandberg (American, 1974) joins Philips from Pear Therapeutics, where as Chief Commercial Officer she led the sales team that built, launched and expanded the prescription digital therapeutics offering. Previously, Ms. Strandberg ran a healthcare consulting firm focused on driving customer growth and prior to that she ran Medtronic’s global healthcare informatics and monitoring business and was global marketing director for the patient monitoring business within Covidien’s Respiratory & Monitoring group, owned by Medtronic was acquired. Ms. Strandberg began her career at 3M, where she held various positions within the company.

“On behalf of the Philips Executive Committee, I am pleased to announce that Julia Strandberg will join Philips as the new Chief Business Leader of the Connected Care business and a member of the Executive Committee,” said Roy Jakobs, CEO of Royal Philips . “Julia brings deep, multidisciplinary expertise, including computer science and surveillance, to Philips. Passionate about improving the healthcare experience for patients and providers across all care settings, Julia understands how to make a difference in the global healthcare ecosystem and brings extensive experience in the development and commercialization of medical technologies.”

Ms. Strandberg succeeds Dan Leonard, who assumed the role of Chief Business Leader Connected Care ad interim when Roy Jakobs became CEO in October 2022.

Philips’ strong brand and compelling purpose speaks to and attracts talent, and the company has therefore continued to strengthen the organization with new health technology talent, including seasoned leaders with in-depth expertise. Ms. Strandberg’s appointment to Philips’ Executive Committee builds on the recent appointments of Wim Appelo as Philips Chief Operations Officer and Steve C. de Baca as Philips Chief Patient Safety & Quality Officer, as well as the promotion of Jeff DiLullo to The Chief Market Philips leader in North America.

More information on the Philips Executive Committee can be found here Here.

For more information please contact:

Ben Zwirs
Philips Global Press Office
Tel: +31 615213446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal healthcare solutions for consumers and professional healthcare solutions for healthcare providers and their patients in the hospital and at home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, surveillance and business informatics, as well as personal health. Philips generated sales of 17.8 billion euros in 2022 and employs around 77,000 people with sales and service in more than 100 countries. For news about Philips, go to www.philips.com/newscenter.

Forward-Looking Statements
This press release contains certain forward-looking statements relating to Philips’ financial condition, results of operations and business and certain of Philips’ plans and objectives relating thereto. Examples of forward-looking statements include statements about strategy, estimates of revenue growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestitures. By their nature, these statements involve risks and uncertainties because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Source link

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close